Viral Infection of HSPC Impacts Hematopoiesis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
HIV-positive patients with a negative or positive viral load.
managed at Ambroise Paré Hospital.
patients with a bone marrow biopsy or myelogram performed as part of their care.
Disqualifiers
None
Trial population
* adult patients. * patients able to read and understand the information note. * no opposition to the use of biological samples. 45 subjects are required in our study: (A) 20 patients with FFPE osteomedullary biopsy prior to COVID-19 pandemic. Including : * 10 HIVpos patients selected based on biopsy results (normal, subnormal/minor lesion). * 10 HIVneg patients selected to match HIVpos patients, considering age and biological sex. (B) 25 HIVneg patients asymptomatic for COVID-19 for whom a myelogram or BM biopsy is prescribed as part of a search for haematological pathology or as part of lymphoma extension investigations.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Evaluate if infected HSPC would modulate the bone marrow environment
Evaluate whether these infected HSPC would modulate the bone marrow environment by upregulating inflammatory cytokines detrimental to lymphopoiesis.
Time frame
at 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov